Novartis Animal Health US, Inc. 3200 Northline Avenue, Suite 300 Greensboro, North Carolina 27408

In Case of Emergency, Call: Novartis Animal Health US, Inc. CHEMTREC

(800)637-0281 (800)424-9300

1. CHEMICAL IDENTIFICATION

Technical Name	Milbemycin Oxime	Product No:	86026
<u>Trade Name(s)</u>	MilbeMite TM OTIC Solution		
Active Ingredient(%)	0.1 %	CAS No:	Not Applicable
Chemical Name	A3 and A4 Oxime		(mixture)
Chemical Class	Macrolide Derivative Canine Anthelmintic	2	

2. COMPOSITION/INFORMATION ON INGREDIENTS

	OSHA	ACGIH		NTP/IARC/OSHA
Materials	PEL	TLV	Other	Carcinogen
Milbemycin Oxime	None	None		Not Listed
Inert Ingredients	None	None		Not Listed

3. HAZARDS IDENTIFICATION

Notes to Physician:

There is no specific antidote if ingested. Induce emesis or lavage stomach. Treat symptomatically based on judgement of the physician, in response to reactions of the patient.

Symptoms of Acute Exposure:

Eye irritation may occur if eye contact is made.

Hazardous Decomposition Products:

None known

Physical Properties:	
Appearance:	Clear and Viscous
Odor:	Odorless

Unusual Fire, Explosion and Reactivity Hazards:

Under normal conditions of use this material does not present a significant fire or explosion hazard.

4. FIRST AID MEASURES

If human exposure is suspected, immediately contact a physician, the nearest hospital, or nearest Poison Control Center. Tell the person contacted the complete product name, chemical class, and type and amount of exposure. Describe any symptoms and follow the advice given.



Ingestion:

If victim is fully conscious, immediately give 1 or 2 glasses of water with medicinal charcoal to drink repeatedly. Never give anything by mouth to an unconscious person.

Eye Contact:

Immediately rinse eyes with a large amount of running water. Hold eyelids apart to rinse the entire surface of the eye and lids. Do not apply any medicating agents except on the advice of a physician.

Skin Contact:

Wash with plenty of soap and water, including hair and under fingernails. Do not apply any medicating agents except on the advice of a physician. Remove contaminated clothing and wash before reuse.

Inhalation:

Move victim from contaminated area to fresh air. Apply artificial respiration if necessary.

Notes to Physician:

There is no specific antidote if ingested. Induce emesis or lavage stomach. Treat symptomatically based on judgement of the physician, in response to reactions of the patient.

Medical Conditions Likely to be Aggravated by Exposure:

None

5. FIRE FIGHTING MEASURES

Fire and Explosion:

Flash Point (Test Method) Not Available Flammable Limits (% in Air) Not Available Autoignition Temperature Not Available Flammability Not Available

Unusual Fire, Explosion and Reactivity Hazards: None Known

In Case of Fire:

Under normal conditions of use this material dose not present a significant fire or explosion hazard. Use dry chemical, foam, or CO_2 extinguishing media. Wear full protective clothing and self-contained breathing apparatus. Evacuate non-essential personnel from the area to prevent human exposure to fire, smoke, fumes, or products of combustion. Prevent use of buildings, area, and equipment until decontaminated.

6. ACCIDENTAL RELEASE MEASURES

In Case of Spill or Leak:

For Clinic use: Cover spill with an absorbent material such as pet litter, sweep up and place in an approved chemical waste container. Wash the area with water containing a strong detergent, absorb with absorbent material, sweep up and place in chemical container. Flush the area with water to remove any residue.

For Bulk product: Wear chemical safety glasses or goggles, rubber gloves, rubber boots, long-sleeved

shirt, long pants, and head covering. Cover with an absorbent material such as pet litter, sweep up and place in an approved chemical waste container. Wash the area with water containing a strong detergent, absorb with absorbent material, sweep up and place in chemical container. Flush the area with water to remove any residue. Do not allow wash water to contaminate water supplies.

7. HANDLING AND STORAGE

Store at room temperature between 59 and 86° F (15-30° C). Shelf-life is 24 months.

8. EXPOSURE CONTROL/PERSONAL PROTECTION

Ingestion:Not required under normal conditions of therapeutic administration and use.Eye Contact:Not required under normal conditions of therapeutic administration and use.Skin Contact:Not required under normal conditions of therapeutic administration and use.Inhalation:Not required under normal conditions of therapeutic administration and use.

9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance:	Clear and Viscous
<u>Odor:</u>	Odorless
Melting Point:	Not Available
Boiling Point:	Not Available
Specific Gravity/Density:	Not Available
<u>pH:</u>	Not Available
Evaporation Rate:	Not Available
Solubility in H20:	Not Available
Vapor Pressure:	Not Available

10. STABILITY AND REACTIVITY

<u>Reactivity:</u> Stability: Stable under normal handling and storage conditions. Hazardous Polymerization: Not available. Conditions to Avoid: Oxidizing agents

Hazardous Decomposition Products: None Known

11. TOXICOLOGICAL INFORMATION

Acute Toxicity/Irritation Studies:

Acute Oral Toxicity:		
LD50:	532-863 mg/kg (rat)	Data based on technical material
Acute Dermal Toxicity:		
LD50	>2000 mg/kg (rat)	Data based on technical material
Acute Inhalation Toxicity:		
LC50	1220 mg/m3 (rat; 4h)	Data based on technical material
Acute Eye Irritation:	Non irritant (rabbit)	Data based on technical material
Acute Skin Irritation:	Non irritant (rabbit)	Data based on technical material
Skin Sensitization:	Not sensitizing (guinea pig)	Data based on technical material

U NOVARTIS

technical material

Mutagenic Potential in Vitro:	Negative	Data based on technical material
Reproductive Hazard Potential:	Not Available	Data based on technical material
Chronic/Subchronic Toxicity Stud	<u>dies:</u> A study was	conducted to evaluate the safety of a 0.1%
milbemycin oxime solution in adu	ılt cats. Topical d	oses at 1x, 3x and 5x the recommended dose
		A study at 1x, 3x or 5x of the recommended 0.1%
		ly for six applications conducted in kittens 4 weeks
		c or local effects. One kitten treated with a .5%
	rs after the second	treatment. In this kitten, lethargy was not observed
after subsequent treatments.		
Carcinogenic Potential:		Not Available
Teratogenicity:		Not teratogenic (rabbit, rat) Data based on

Toxicity of Other Components:

Not Available

Target Organs:Active Ingredients:None KnownInert Ingredients:None Known

12. ECOLOGICAL INFORMATION

Summary of Effects:	Not Available
Eco-Acute Toxicity:	Not Available
Eco-Chronic Toxicity:	Not Available
Environmental Fate:	Not Available

13. DISPOSAL CONSIDERATION

Disposal: Dispose of product containers, waste containers, and residues according to local, state, and federal health and environmental regulations.

Characteristic Waste:Not AvailableListed Waste:Not Available

14. TRANSPORT INFORMATION

DOT Classification: Not applicable, No label or placard required

B/L Freight Classification: Pharmaceutical Chemical, N.O.S.

International Transportation: Not Available

15. REGULATORY INFORMATION

SARA Title III Classification:Section 311/312:NoneSection 313 chemical(s):None

<u>Proposition 65:</u> No component listed on California Prop. 65 List. <u>CERCLA Reportable Quantity (RO):</u> Not Available **<u>RCRA Classification</u>**: Not Applicable

TSCA Status: Not Available

16. OTHER INFORMAT	ION

NFPA Hazard Ratings:Health:0Flammability:0Reactivity:0

0 Least 1 Slight 2 Moderate 3 High 4 Severe

Questions concerning the safe handling of this product should be referred to:

Novartis Animal Health US, Inc. 1-800-637-0281

Issued Date: Revised Date: October 1, 2001 January 16, 2002

Supersedes: O

October 1, 2001

The information and recommendations contained herein are based upon data believed to be correct. However, no guarantee or warranty of any kind, expressed or implied, is made with respect to the information contained herein.